Amneal Pharmaceuticals is trading 4.04% down at $19.34, with the decline appearing to reflect profit-taking after FDA approval and immediate launch of generic lanreotide.
- On September 21, it gained 7.75% to $20.16.
- No new negative company announcement or analyst downgrade was identified for September 22.
- Broader markets were largely mixed, limiting evidence of a macro-driven decline.